Trius Therapeutics, Inc. (TSRX) Message Board
-
Lot's of good can be done with a bunch of money. 5 years in the making for me. IFOS is a very nasty drug. I will be very happy when it no longer has to be used.
-
ZIOPHARM Oncology Announces Initiation of Indiana University-Sponsored Phase 2 Study of Palifosfamide in Recurrent and Incurable Germ Cell (Testicular and Ovarian) Tumors
Folks, you need to look beyond limited STS market. Einhorn is the same Doc running SCLC trial. Do you really think he would initiate a new one if the drug is not showing signs of efficacy??? -
I think financials are due out soon. Hopefully we get an update.
-
B*LLs of steel. I will take your wager. If I lose, I will have more free time!
-
The only dilution coming is when I add a wee bit of water to my scotch tonight.
-
Hopefully we get news soon.
-
BTTB, Seriously, I would hold a few. If IL-12 holds promise this could be one for the ages.
-
I cannot believe The Houghton Regime ended 9-30-11. That is almost 1 1/2 years ago. Amazing.
CorMedix To Shelve Neutrolin Program In U.S; CEO John Houghton To Step Down
RELATED NEWS
CorMedix Promotes Randy Milby To CEO - Quick Facts
Trade CRMD now with
9/30/2011 5:03 PM ET
CorMedix, Inc. (CRMD: Quote), a development-stage biopharmaceutical company, Friday said it has decided based upon recent developments to primarily focus on the commercialization of Neutrolin in Europe.
As announced on July 7, 2011, CorMedix anticipates being in a position to obtain CE Marking approval in the first half of 2012.
The receipt of CE Marking approval will enable the company to market and sell Neutrolin in countries that accept CE Marking, which include the 27 countries of the European Union.
As noted in its July 7, 2011 press release, "the Company is in discussion with several companies for potential strategic alliances as an option to commercialize Neutrolin® in the European market next year."
By preserving its current cash, in addition to potentially receiving non-dilutive funding from state and federal applications, CorMedix expects that its existing resources will be sufficient to fund operations into the fourth quarter of 2012 without having to raise significant amounts of additional capital.
CorMedix said it would continue to evaluate the status of Neutrolin and its proprietary formulation of deferiprone in the U.S. However, given their current status, the company does not expect to expend any material amounts in the U.S. before the CE Marking status of Neutrolin in Europe is finalized.
If the European strategic plan is successful, the company believes the European commercialization of Neutrolin might be sufficient to fund much of the future U.S. clinical development costs.
In another development, Bridgewater, New Jersey-based CorMedix announced a mutual separation agreement with CEO John Houghton, after the company and Houghton mutually agreed not to renew Houghton's employment agreement. As per the agreement, Houghton would provide the company certain transition services on an as-needed basis through the end of 2011.
In the interim, Richard Cohen, a member of the Board of Directors, would serve as the company's Executive Chairman in a non-employee capacity. -
If, if, if we get good news......where do they find that many shares?
- Reply to
Better tolerability of Pali will translate to better OS.
by michaelangelo94 •Mar 2, 2013 11:25 AMOS is a stretch in STS but we'll see. I do believe better tolerability likely means in a head to head with IFOS, this becomes the preferred treatment option. All that is down the road. I think good PFS #s (3 months plus) and a clean safety profile will be more then enough to get this through. Given the trial extension, It would not surprise me if they crack 4 months PFS.
Where the heck do you get 12MM shares? Likely some of the recent call buying is folks who are hedging their bear bets. - Reply to
Adam F Predicts Postitive Results - Shorts Squeeze Over $5.00 Soon
by prophit05 •Mar 1, 2013 9:23 AMMany of the short-side board guys are simply paid to post and have no position. That is the nature of thr game. All biotech is based on perception and right now they have successfully muddied the waters.
-
Shorts have done a great job of sowing doubt here. Data will prevail in the end.
-
I think the AM print was a head fake to try to create interest. Someone is selling. Let them sell.
-
Let us hope so. Pali could be a very big drug one day. Folks are focused on STS but that may just be the beginning. IFOS is a bad drug re: side effects. Pali has the same mechanism of action but is likely to be better tolerated. I continue to see it as the eventual replacement for IFOS across the board.
-
Well, hopefully we get news soon. March is upon us.
-
Who knows. it could have been some type of cross. I remain hopeful here.
-
Maybe some Euro-Regulator loaded up! : )
-
Maybe the man found a concience. He was always pretty positive on ZIOP prior to that silly article on his micro-cap rule.
-
What the heck was that?
-
"It's not given to human beings to have such talent that they can just know everything about everything all the time. But it is given to human beings who work hard at it - who look and sift the world for a misplaced bet - that they can occasionally find one."
- Charlie MungerSentiment: Buy